The AEGEAN - Assessment of an Education and Guidance program for Eliquis Adherence in Non-valvular atrial fibrillation brand, founded in 2012 (United States), from 496 sister brands and 17477 competing brands. AEGEAN - Assessment of an Education and Guidance program for Eliquis Adherence in Non-valvular atrial fibrillation is a brand of BRISTOL-MYERS SQUIBB COMPANY, listed on the stock exchange of New York. AEGEAN - Assessment of an Education and Guidance program for Eliquis Adherence in Non-valvular atrial fibrillation belongs to the Drug Manufacturers business sector.
Share price and profitability of the share BRISTOL-MYERS SQUIBB COMPANY (AEGEAN - Assessment of an Education and Guidance program for Eliquis Adherence in Non-valvular atrial fibrillation)
Buy BRISTOL-MYERS SQUIBB COMPANY share with
(0% commission and fractional shares)
Your capital is subject to risk. Other fees apply. For more information, visit etoro.com/trading/fees.
Investment simulator :
Portfolio valuation
BRISTOL-MYERS SQUIBB COMPANY
(AEGEAN - Assessment of an Education and Guidance program for Eliquis Adherence in Non-valvular atrial fibrillation)
over 5 years*
USD 52.96
Stock market history BRISTOL-MYERS SQUIBB COMPANY (AEGEAN - Assessment of an Education and Guidance program for Eliquis Adherence in Non-valvular atrial fibrillation)
*non inclusive of dividends, non inclusive of market orders
past performances do not prejudice future performances
past performances do not prejudice future performances
